Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial.
Viking Therapeutics stock surged by 36% after unveiling promising data from a weight-loss drug clinical trial, sparking questions about the company's potential. While Eli Lilly and Novo Nordisk maintain their leading positions in the weight loss drug market, Viking Therapeutics (NASDAQ: VKTX) is making noteworthy progress in clinical stages.
Recently, the clinical-stage biotech experienced a significant rise in its stock price, jumping over 30% in a single day. To understand the implications of these results, it is essential to delve into the mechanism behind GLP-1-based weight loss medicines. These medications function by imitating naturally occurring hormones like GLP-1, which promote feelings of fullness. This leads patients to consume fewer calories, ultimately contributing to weight loss.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.